MX2016006006A - Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer. - Google Patents
Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer.Info
- Publication number
- MX2016006006A MX2016006006A MX2016006006A MX2016006006A MX2016006006A MX 2016006006 A MX2016006006 A MX 2016006006A MX 2016006006 A MX2016006006 A MX 2016006006A MX 2016006006 A MX2016006006 A MX 2016006006A MX 2016006006 A MX2016006006 A MX 2016006006A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- extract
- species
- management
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/577—Malvaceae (Mallow family)
- A61K36/5777—Theobroma, e.g. cocao or cocoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un método para el manejo del cáncer y para el tratamiento de las comorbilidades del cáncer, incluyendo pero sin limitarse a la fatiga relacionada con el cáncer, caquexia, anorexia, dolor, anemia, astenia, depresión, debilidad muscular, nausea, vómito, lesiones adversas en la piel y en los apéndices de la piel; dicho método comprende la administración tanto por las vías convencionales como no convencionales: oral, tópica, parenteral, inyección intratumoral o una combinación de ellos, o la administración como potenciador adyuvante en otros tratamientos utilizando las vías mencionadas, de una composición que contenga como ingrediente activo un extracto de la especie AIIium, la cual contiene quercetina, un extracto de las especies Citrus y un extracto de la especie Paullinia y un extracto de la especie Theobroma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901631P | 2013-11-08 | 2013-11-08 | |
| PCT/EP2014/074048 WO2015067759A1 (en) | 2013-11-08 | 2014-11-07 | Method for the management of cancer and treatment of cancer comorbidities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006006A true MX2016006006A (es) | 2016-07-18 |
Family
ID=51868963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006006A MX2016006006A (es) | 2013-11-08 | 2014-11-07 | Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10357531B2 (es) |
| EP (1) | EP3065751B1 (es) |
| JP (1) | JP6742904B2 (es) |
| KR (1) | KR102344748B1 (es) |
| CN (2) | CN115350236A (es) |
| AU (1) | AU2014345539B2 (es) |
| BR (1) | BR112016009931B1 (es) |
| CA (1) | CA2928675C (es) |
| DK (1) | DK3065751T3 (es) |
| ES (1) | ES2777250T3 (es) |
| HK (1) | HK1223844A1 (es) |
| MX (1) | MX2016006006A (es) |
| PL (1) | PL3065751T3 (es) |
| PT (1) | PT3065751T (es) |
| RU (1) | RU2016117205A (es) |
| WO (1) | WO2015067759A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2862598A1 (en) | 2013-10-16 | 2015-04-22 | Legacy Healthcare Holding Ltd. | Use of a composition for the pigmentation of hair and hairs |
| WO2017186954A1 (en) * | 2016-04-28 | 2017-11-02 | Legacy Healthcare Ltd | Method for the improvement of speed and endurance capacity |
| CN113164440A (zh) * | 2018-11-30 | 2021-07-23 | 贝斯以色列女执事医疗中心有限公司 | 减少癌症患者的主要血栓事件的组合物和方法 |
| FR3109881B1 (fr) * | 2020-05-07 | 2022-10-21 | Legacy Healthcare Switzerland Sa | Procede pour ameliorer le systeme immun pour acquerir la pan-immunite |
| US11819530B1 (en) | 2023-05-17 | 2023-11-21 | Legacy Healthcare (Switzerland) Sa | Long term treatment of hair loss |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2844614A1 (de) | 1978-10-13 | 1980-05-08 | Alfred Czypull | Bio-aktiv-haartinktur |
| JPH04342517A (ja) | 1990-07-20 | 1992-11-30 | Yutaka Miyauchi | ５α−リダクターゼ阻害剤 |
| CH682217A5 (en) | 1991-05-23 | 1993-08-13 | Linda Singer Dolla | Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness |
| FR2706771A1 (en) | 1993-06-21 | 1994-12-30 | Pelletier Jacques | Formula for the treatment of certain cancers. |
| JP3233813B2 (ja) | 1995-03-31 | 2001-12-04 | 株式会社マンダム | チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料 |
| DE19533777A1 (de) | 1995-09-12 | 1997-03-13 | Walther Aria Ellen | Haarwuchsmittel |
| JP3527584B2 (ja) | 1996-01-23 | 2004-05-17 | 株式会社ナリス化粧品 | 養毛・育毛剤 |
| US5773241A (en) | 1996-09-05 | 1998-06-30 | Ericsson; Arthur Dale | Preparation of bioactive extracts |
| JP2000044439A (ja) | 1998-07-31 | 2000-02-15 | Shiseido Co Ltd | 頭皮頭髪用組成物 |
| JP2000247830A (ja) | 1999-02-26 | 2000-09-12 | Nagase & Co Ltd | エラスターゼ阻害剤 |
| EP1228769A1 (de) | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiontisches Regenerativum |
| US6582702B2 (en) * | 2001-07-10 | 2003-06-24 | Alvin Foster Rigby | Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality |
| US20030077336A1 (en) | 2001-10-10 | 2003-04-24 | Maf Group, Llc | Anti-inflammatory complex containing flaxseed oil |
| JP2003201229A (ja) | 2001-10-23 | 2003-07-18 | Shiseido Co Ltd | マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料 |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| BR0203591A (pt) * | 2002-09-05 | 2004-05-25 | Marc Kipfer | Bebida reidratante e energética natural a base de água-de-coco, sucos de frutas e componentes nutritivos incorporados |
| DE102004011968A1 (de) | 2004-03-10 | 2005-09-29 | Henkel Kgaa | Präbiotisch wirksame Pflanzenextrakte |
| KR20070022018A (ko) | 2004-03-19 | 2007-02-23 | 네스텍소시에테아노님 | 기능성 재료의 전달 |
| MY142017A (en) * | 2004-03-19 | 2010-08-16 | Nestec Sa | Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same |
| EP1604647B1 (en) | 2004-05-12 | 2008-05-07 | Chisso Corporation | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof |
| WO2005120452A1 (en) | 2004-06-07 | 2005-12-22 | Katica Pavlovic | A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs |
| FR2865132A1 (fr) | 2004-07-06 | 2005-07-22 | Oreal | Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux |
| DE202004012348U1 (de) | 2004-08-03 | 2004-10-07 | Jabal Amman, Suhbi Hasan Mohammes | Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem |
| US7462595B2 (en) * | 2004-09-17 | 2008-12-09 | Prange Jr Arthur Jergen | Methods for treating cancer-related fatigue |
| JP2006104098A (ja) | 2004-10-04 | 2006-04-20 | Ichimaru Pharcos Co Ltd | ヒアルロニダーゼ活性阻害剤 |
| FR2877219B1 (fr) | 2004-10-28 | 2007-03-09 | Fatima Basri | Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene |
| FR2877576B1 (fr) | 2004-11-08 | 2007-03-09 | Ahmed Kadri | Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes |
| DE102005010142A1 (de) | 2005-03-02 | 2005-11-03 | Dr. Kurt Wolff Gmbh & Co. Kg | Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels |
| JP4804805B2 (ja) | 2005-06-10 | 2011-11-02 | 横関油脂工業株式会社 | 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤 |
| WO2008015341A2 (fr) | 2006-08-03 | 2008-02-07 | Societe D'extraction Des Principes Actifs Sa (Vincience) | Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes |
| FR2912310B1 (fr) * | 2007-02-13 | 2009-08-07 | Kasan Sarl | Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications. |
| WO2008127827A1 (en) * | 2007-03-14 | 2008-10-23 | The Hershey Company | Health bars and compositions for improving mental and physical energy |
| US20080305096A1 (en) | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
| FR2939646B1 (fr) | 2008-12-12 | 2017-04-14 | Oreal | Procede de coloration capillaire a partir d'une composition comprenant au moins un orthodiphenol, un sel metallique, du peroxyde d'hydrogene, du (bi)carbonate et un agent alcalinisant |
| KR102021075B1 (ko) * | 2009-06-22 | 2019-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| WO2011005310A1 (en) * | 2009-07-07 | 2011-01-13 | Robert Shorr | Pharmaceutical composition |
| EP2600822A2 (en) | 2010-08-05 | 2013-06-12 | Legacy Healthcare Holding Ltd. | Method for stimulating hair growth |
| CN103533945A (zh) | 2011-02-23 | 2014-01-22 | 传世健康护理有限公司 | 预防化疗和放疗诱发的脱发（cria）、降低cria影响和改善cria后毛发再生表象的组合物的新用途 |
| WO2012140013A2 (en) | 2011-04-11 | 2012-10-18 | Legacy Healthcare Holding Ltd | New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling. |
| WO2013020719A2 (en) * | 2011-08-09 | 2013-02-14 | Legacy Healthcare Holding Ltd | New use of compositions to delay the onset of the catagen phase of the hair |
| EP2862598A1 (en) | 2013-10-16 | 2015-04-22 | Legacy Healthcare Holding Ltd. | Use of a composition for the pigmentation of hair and hairs |
-
2014
- 2014-11-07 BR BR112016009931-1A patent/BR112016009931B1/pt active IP Right Grant
- 2014-11-07 MX MX2016006006A patent/MX2016006006A/es unknown
- 2014-11-07 EP EP14795825.0A patent/EP3065751B1/en active Active
- 2014-11-07 CN CN202211114854.3A patent/CN115350236A/zh active Pending
- 2014-11-07 KR KR1020167013957A patent/KR102344748B1/ko not_active Expired - Fee Related
- 2014-11-07 HK HK16112239.8A patent/HK1223844A1/zh unknown
- 2014-11-07 AU AU2014345539A patent/AU2014345539B2/en active Active
- 2014-11-07 PT PT147958250T patent/PT3065751T/pt unknown
- 2014-11-07 JP JP2016528184A patent/JP6742904B2/ja active Active
- 2014-11-07 PL PL14795825T patent/PL3065751T3/pl unknown
- 2014-11-07 WO PCT/EP2014/074048 patent/WO2015067759A1/en not_active Ceased
- 2014-11-07 DK DK14795825.0T patent/DK3065751T3/da active
- 2014-11-07 US US15/032,179 patent/US10357531B2/en active Active
- 2014-11-07 CN CN201480060350.5A patent/CN105682671A/zh active Pending
- 2014-11-07 ES ES14795825T patent/ES2777250T3/es active Active
- 2014-11-07 CA CA2928675A patent/CA2928675C/en active Active
- 2014-11-07 RU RU2016117205A patent/RU2016117205A/ru not_active Application Discontinuation
-
2019
- 2019-06-26 US US16/453,379 patent/US20190314441A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160256512A1 (en) | 2016-09-08 |
| JP6742904B2 (ja) | 2020-08-19 |
| AU2014345539A1 (en) | 2016-05-19 |
| RU2016117205A3 (es) | 2018-08-09 |
| JP2016535753A (ja) | 2016-11-17 |
| US20190314441A1 (en) | 2019-10-17 |
| EP3065751A1 (en) | 2016-09-14 |
| US10357531B2 (en) | 2019-07-23 |
| RU2016117205A (ru) | 2017-12-11 |
| KR102344748B1 (ko) | 2021-12-30 |
| CN115350236A (zh) | 2022-11-18 |
| AU2014345539B2 (en) | 2020-04-23 |
| WO2015067759A1 (en) | 2015-05-14 |
| HK1223844A1 (zh) | 2017-08-11 |
| DK3065751T3 (da) | 2020-03-09 |
| CA2928675A1 (en) | 2015-05-14 |
| PL3065751T3 (pl) | 2020-07-13 |
| CA2928675C (en) | 2023-09-05 |
| ES2777250T3 (es) | 2020-08-04 |
| AU2014345539A8 (en) | 2016-05-26 |
| CN105682671A (zh) | 2016-06-15 |
| BR112016009931B1 (pt) | 2021-02-02 |
| EP3065751B1 (en) | 2019-12-18 |
| PT3065751T (pt) | 2020-03-06 |
| KR20160074006A (ko) | 2016-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| UY28862A1 (es) | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| AR102372A1 (es) | Composición que comprende una mezcla de extractos vegetales o una mezcla de moléculas contenidas en dichos vegetales, y su utilización para actuar sobre el metabolismo glucídico y/o lipídico | |
| MD4577B1 (ro) | Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| MX2011011514A (es) | Formulaciones de canabidiol y metodos para utilizarlas. | |
| MX2016006006A (es) | Metodo para el manejo del cancer y para el tratamiento de las comorbilidades relacionadas con el cancer. | |
| MX393613B (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| MX2014012742A (es) | Composicion para el tratamiento de transtornos metabólicos. | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| BR112016029888A2 (pt) | composições parasiticidas compreendendo derivados de indol, métodos e usos dos mesmos | |
| NI201500007A (es) | Formulación transdérmica que contiene inhibidores de cox | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MX2019004191A (es) | Composiciones de alimentos y bebidas que comprenden inhibidores de pde5. | |
| CR20160021A (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio | |
| AR101673A1 (es) | Composición para el tratamiento de neuropatías y del dolor neuropático | |
| NI201200196A (es) | Agentes terapéuticos 976 | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
| PA8657901A1 (es) | Composicion que comprende una epotilona y metodos para producir dicha composicion | |
| CR20160116A (es) | Método para tratar onicomicosis con hidroxipropil quitasano |